Simplification of PBS restrictions for T2DM medicines

  • Removal of the requirement for patients to be contraindicated to metformin, to use DPP4 inhibitors, SGLT2 inhibitors, or GLP-1 RAs with insulin.5
  • Alignment of DPP4 inhibitor restrictions to allow use of all DPP4 inhibitors with insulin or SGLT2 inhibitors.1
  • Pioglitazone has been changed to a Restricted Benefit listing for T2DM without any clinical criteria. This provides an additional first-line therapy for patients who are contraindicated or intolerant to other first-line therapies.5
  • DPP4 inhibitors and SGLT2 inhibitors are now subsidised for use in quadruple therapy, in combination with each other, metformin, and insulin.5

Please refer to the PBS eligibility requirements for T2DM medicines flow diagram and the Tabular summary of new PBS restrictions for T2DM medicines on the PBS website for further details.

 

  1. Paxlovid® (nirmatrelvir and ritonavir) Pharmaceutical Benefits Scheme. Canberra: Australian Government Department of Health and Aged Care; 2024 Available from: https://www.pbs.gov.au/medicine/item/12996B 13147Y (accessed 6 June 2024).

 

  1. PBS restriction changes to type 2 diabetes mellitus (T2DM) medicines. Canberra: Australian Government Department of Health and Aged Care; 2024 Available from: www.pbs.gov.au/info/reviews/pbs-restriction-changesto-type-2-diabetes-mellitus-t2dm-medicines (accessed 6 June 2024)
Back to top